alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › lecanemab-treatment

lecanemab-treatment

5 studies tagged lecanemab-treatment, dated 2025-08-21 to 2026-10-20. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Amyloid PET Changes During Lecanemab Treatment in Patients With and Without Amyloid-related Imaging Abnormalities 2026-10-20
  2. Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from a Cohort Study from the Alzheimer's Research and Treatment Center 2026-10-12
  3. Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment 2026-09-15

Studies

5 studies carry this tag.

Date range

2025 to 2026

Top journals

  • Clinical nuclear medicine 1
  • Current Alzheimer research 1
  • Internal medicine (Tokyo, Japan) 1
  • Journal of Alzheimer's disease : JAD 1
  • Journal of Alzheimer's disease reports 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Amyloid PET Changes During Lecanemab Treatment in Patients With and Without Amyloid-related Imaging Abnormalities

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Clinical nuclear medicine 2026-10-20 Treatments

    Lecanemab reduces cerebral amyloid-β burden in Alzheimer disease, but whether amyloid-related imaging abnormalities (ARIA) are associated with greater amyloid clearance remains unclear.

  2. Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from a Cohort Study from the Alzheimer's Research and Treatment Center

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Current Alzheimer research 2026-10-12 Treatments

    Our single-center experience with long-term lecanemab treatment was similar to that observed in clinical trials.

  3. Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease : JAD 2026-09-15 Treatments

    Amyloid-related imaging abnormalities (ARIA) are a safety concern during lecanemab treatment for early Alzheimer's disease.

  4. Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case report

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Alzheimer's disease reports 2026-01-01 Treatments

    Lecanemab is an anti-amyloid-β protofibril antibody that slows cognitive decline in early Alzheimer's disease.

  5. Amyloid Clearance and Transient CSF Aβ40 Reduction in a Case of ARIA-E/H Following Lecanemab Treatment

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Internal medicine (Tokyo, Japan) 2025-08-21 Treatments

    We herein report a case of amyloid-related imaging abnormalities (ARIA)-E/H following lecanemab treatment in a 70-year-old man with mild cognitive impairment due to Alzheimer's disease.

All topic tags with their study counts